Out Now: AmoyDx® FGFR1-4 NGS Panel
Detection of mutations and fusions in the FGFR1, FGFR2, FGFR3 and FGFR4 genes
Following its recent announcement, the AmoyDx® FGFR1-4 NGS Panel (RUO) is now available offering a robust NGS assay for the qualitative detection of mutations (SNVs, InDels) and fusions in FGFR1-4 genes at DNA and RNA levels, respectively. The panel covers the full coding sequences of all four genes and utilizes a hybrid capture technology (ddCAP) for library preparation. Its optimized DNA/cDNA co-library preparation workflow mostly takes place within a single reaction tube, enhancing efficiency and ease of use.
Learn more here.
For further information, please contact us at molpath@zytomed-systems.de
Further topics
IVDR Update October 2022
As a manufacturer and distributor of in vitro diagnostics, our enterprise group with the companies Zytomed Systems GmbH and ZytoVision GmbH attaches great importance to the timely implementation of the requirements of the IVDR (Regulation (EU) 2017/746 of the European Parliament and of the Council of April 5th 2017 on in vitro diagnostic medical devices).
